Many countries, including Australia, regulate the price consumers pay for pharmaceuticals. In this paper, the Australian Pharmaceutical Benefits Scheme (PBS) is modelled as a multi-stage game played between the regulator and pharmaceutical firms. Conditions are derived under which vertically differentiated firms are regulated and a number of issues are discussed. These include efficiency, regulated firm profitability, leakage, and price discrimination. An extension examines the introduction of new drugs and concludes that if all the benefits of a new drug are to be realised, then existing agreements and transfers (per-unit subsidies) need to be renegotiated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jhealeco.2003.11.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The challenges of regulatory pluralism.
Health Policy
November 2024
KPM Center for Public Management, University of Bern, Freiburgstr. 3, 3010 Bern, Switzerland; Swiss Institute for Translational and Entrepreneurial Medicine (sitem-insel), Freiburgstr. 3, 3010 Bern, Switzerland.
Countries with small and/or less-resourced regulatory authorities that operate outside of a larger medical product regulatory system face a regulatory strategy dilemma. These countries may rely on foreign well-resourced regulators by recognising the regulatory decisions of large systems and following suit (regulatory reliance); alternatively, such countries may extend formal decision recognition to regulators in multiple other jurisdictions with similar oversight and public health goals, following a system which we call regulatory pluralism. In this policy comment, we discuss three potential limitations to regulatory pluralism: (i) regulatory escape, in which manufacturers exploit regulatory variation and choose the lowest regulatory threshold for their product; (ii) increased fragmentation and complexity for countries adopting this approach, which may, in turn, lead to inconsistent processes; and (iii) loss of international bargaining power in developing regulatory policies.
View Article and Find Full Text PDFAnalyzing the Benefits and Costs of the Safe Step Act on Patients, Physicians, and Insurers.
J Psoriasis Psoriatic Arthritis
July 2024
Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Pharmaceutical expenditures in the United States, particularly in dermatology, have grown rapidly, driven by expensive topical and biologic treatments. Insurers are employing cost-containing strategies such as step therapy, which mandates the use of lower-cost treatments before more expensive medications. The bipartisan Safe Step Act aims to enhance step therapy policies by introducing a transparent process for requesting exceptions and reasonable timelines for the process.
View Article and Find Full Text PDFHas the human biological interaction with SARS-CoV2 variants entered a pliant "Faustian bargain"?
Pharmacol Res Perspect
August 2024
Centre for Drug Repurposing and Medicines Research, University of Newcastle and Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
Article Synopsis
- - The authors suggest that a "Faustian bargain" exists in COVID-19, where getting a higher SARS-CoV2 viral load might reduce the risk of severe lower lung infections.
- - This idea connects to thermodynamics and how well the virus binds to cell receptors, indicating that these scientific principles can help explain the observed health outcomes.
- - The hypothesis aims to clarify why COVID-19 has caused varied health impacts, including both illness and death, by looking at the balance between infection levels and lung disease risk.
Improved CNS Control With the Addition of Chemotherapy to Osimertinib: A Devil's Bargain?
J Clin Oncol
June 2024
Yao Yu, MD, Emily Miao, PharmD, and Luke R.G. Pike, MD, DPhil, Memorial Sloan Kettering Cancer Center, New York, NY.
Diversely functionalized isoquinolines and their core-embedded heterocyclic frameworks: a privileged scaffold for medicinal chemistry.
RSC Med Chem
December 2023
School of Chemical Sciences, Mahatma Gandhi University Kottayam 686560 India
Isoquinoline-enrooted organic small-molecules represent a challenging molecular target in the organic synthesis arsenal attributed to their structural diversity and therapeutic importance. Into the bargain, isoquinolines are significant structural frameworks in modern medicinal chemistry and drug development. Consequently, synthetic organic and medicinal chemists have been intensely interested in efficient synthetic tactics for the sustainable construction of isoquinoline frameworks and their derivatives in enantiopure or racemic forms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!